Breast tumor kinase (BRK) is an intracellular tyrosine kinase expressed in differentiating epithelial cells of the gastrointestinal tract and skin, and in several epithelial cancers including carcinomas of the breast and colon. We examined expression of BRK and its mouse ortholog Srcrelated intestinal kinase (Sik) in prostate tissues and detected it in the nuclei of normal luminal prostate epithelial cells. BRK localization was then examined in 58 human prostate biopsy samples representing various grades of prostate cancer. While nuclear localization of BRK was present in well-differentiated tumors, it was absent in poorly differentiated tumors. However localization of Sam68, a nuclear substrate of BRK/Sik, was unaltered in all prostate tumors examined. Consistent with these results, nuclear BRK was detected in the more differentiated androgen-responsive LNCaP human prostate cancer cell line that is poorly tumorigenic in host animals, but it was primarily cytoplasmic in the undifferentiated androgen-unresponsive PC3 prostate cancer cell line that forms aggressive tumors. While PC3 cells expressed higher levels of endogenous BRK than LNCaP cells, BRK was less active in these cells. Our data suggest that BRK plays a role in differentiation of prostate epithelial cells. Altered BRK localization and/or activity may provide a prognostic indicator for prostate tumor progression and be a potential target for therapeutic intervention.
Introduction
Prostate cancer is a complex disease, involving multiple molecular events that lead to the transformation of prostate epithelial cells (reviewed in Abate-Shen and Shen, 2000) . Several growth factor families that act through receptor tyrosine kinases have been shown to contribute to growth of prostate tumors, including the fibroblast growth factor (FGF) family, the IGF family, EGF, and TGF-a (reviewed in Djakiew, 2000; Hellawell and Brewster, 2002) . Binding of growth factors to their cognate tyrosine kinase receptors results in receptor dimerization and autophosphorylation. This is followed by recruitment of signaling molecules containing SH2 and SH3 domains that then interact to transmit the growth factor signal to the nucleus (Blume-Jensen and Hunter, 2001 ). These signaling proteins may include intracellular tyrosine kinases, such as members of the Src family. Regulation of tyrosine kinase signaling pathways may play a significant role in the progression of prostate tumors, as the tumors become metastatic and shift from androgen-dependent to androgen-independent growth (Feldman and Feldman, 2001) .
The intracellular breast tumor kinase (BRK) was cloned from a human metastatic breast tumor in a screen for protein tyrosine kinases involved in breast cancer (Mitchell et al., 1994) . BRK is expressed in many breast carcinoma cell lines and in a high percentage of primary breast tumors that have been examined, but it has not been detected in normal human breast tissue (Mitchell et al., 1994; Barker et al., 1997) , or at any stage of mammary gland differentiation in the mouse (Llor et al., 1999) . BRK was also cloned from cultured human melanocytes and designated PTK6 . It was subsequently found to be expressed in metastatic melanoma cell lines but not in normal melanocytes (Easty et al., 1997) . Moderate increases in BRK levels were detected in colon tumors (Llor et al., 1999) .
The mouse ortholog of BRK, referred to as Srcrelated intestinal kinase (Sik), was initially cloned from the mouse small intestine (Siyanova et al., 1994) . Sik is expressed in differentiating epithelial cells, and has been detected in the skin and the linings of the gastrointestinal tract (Vasioukhin et al., 1995) . It is rapidly activated during differentiation of cultured keratinocytes, and overexpression of Sik in an embryonic mouse keratinocyte cell line resulted in increased expression of the differentiation marker filaggrin during differentiation (Vasioukhin and Tyner, 1997) . BRK expression has also been detected in differentiating epithelial cells throughout the human gastrointestinal tract (Llor et al., 1999) . These data suggest that BRK/Sik participates in signal transduction pathways that regulate differentiation.
BRK/Sik is an intracellular tyrosine kinase that contains SH2 and SH3 domains. In contrast to members of the Src-family, it has a short unique amino terminus and lacks a myristoylation signal (Mitchell et al., 1994; Vasioukhin et al., 1995) . Thus far two substrates have been identified for BRK/Sik, and these include the novel adaptor-like protein BKS (Mitchell et al., 2000) and the nuclear RNA-binding protein Sam68 (Derry et al., 2000) . Sam68 is a member of the STAR family of KHdomain containing RNA-binding proteins that regulate RNA metabolism (Vernet and Artzt, 1997) . In cancer cell lines Sam68 is localized to unique nuclear structures termed Sam68/SLM nuclear bodies (SNBs) that also contain the Sam68-like mammalian proteins SLM1 and SLM2 (Chen et al., 1999) . After stress such as heat shock, Sam68 can also be found in stress-induced nuclear bodies (Denegri et al., 2001) . Although Sam68 can be phosphorylated by other intracellular tyrosine kinases, only BRK/Sik has been shown to colocalize with Sam68 in the nucleus (Derry et al., 2000) .
Several studies indicate that Sam68 regulates RNA metabolism. Sam68 was found to act as a functional homolog of the human immunodeficiency virus type 1 (HIV1) Rev protein, which transports RNA from the nucleus to the cytoplasm (Reddy et al., 1999; Soros et al., 2001) . Phosphorylation of Sam68 by BRK/Sik inhibits its ability to bind RNA and to function as a cellular Rev homolog (Derry et al., 2000) . Sam68 has been shown to influence the utilization of specific RNAs in the cytoplasm and this is also functionally regulated by BRK/Sik (Coyle et al., 2003) . In addition, Sam68 colocalizes with and associates with RNA splicing factors (Hartmann et al., 1999; Denegri et al., 2001) , and was recently shown to be a regulator of alternative splicing (Matter et al., 2002) .
The ability of BRK/Sik to regulate negatively the RNA-binding activities of Sam68 may have an impact on cell growth and differentiation. It has been suggested that RNA-binding functions of Sam68 positively regulate cell growth because a variant of Sam68 lacking a functional KH domain inhibits cell cycle progression (Barlat et al., 1997) . Sam68 is also a direct target of Cdc2 during mitosis (Resnick et al., 1997) and an extracellular signal-regulated kinase (ERK) target (Matter et al., 2002) .
Here we describe the expression of BRK and its ortholog Sik in the adult human and mouse prostate, respectively, and show that the BRK/Sik kinase is localized to the nuclei of prostate epithelial cells in both species. We surveyed BRK expression in a panel of human prostate biopsy samples and tumor cell lines, and found that BRK localization is altered in prostatic intraepithelial neoplasia and in different grades of prostate cancer. Relocalization of the BRK/Sik kinase during development of prostate cancer may indicate disruption of a signaling pathway important for maintaining the normal phenotype of prostate epithelial cells.
Results
BRK and Sik are expressed in the nuclei of normal human and mouse prostate secretory epithelial cells Using immunohistochemistry we examined the expression of BRK and Sik in sections of adult human and mouse prostate, respectively (Figure 1 ). We detected striking BRK and Sik expression in the nuclei of luminal prostate epithelial cells. While BRK/Sik was previously shown to localize to the nuclei of cultured epithelial cells, nuclear localization of BRK/Sik was not observed in colon tissue samples (Llor et al., 1999) . The prostate is the first tissue where significant BRK/Sik nuclear localization has been detected. The nuclear localization of BRK/Sik is significant, as we previously identified a nuclear substrate, Sam68, which is phosphorylated by this kinase (Derry et al., 2000) .
BRK localization is altered in poorly differentiated prostate tumors
In all, 58 individual paraffin-embedded human prostate surgical samples were graded according to Gleason's microscopic grading system by a board-certified pathologist. Gleason's system involves histological examination of the sample and grading based on the pattern of glandular formation. Numbers from 1 to 5 are assigned, with lower numbers representing well-differentiated structures, and higher numbers indicating poorly differentiated regions (Gleason and Mellinger, 1974) . In general, the prevalent grade in each of the 58 samples was analysed.
Among the samples examined, normal, benign, preneoplastic, and malignant conditions were observed. Sections from each surgical sample were stained with anti-BRK antibodies and two individuals analysed the sections by scoring at least three fields per slide using light microscopy. The intensity of BRK nuclear staining was given a score on a scale from 0 to 100%, with 100% representing the intensity as displayed in the normal glands, since they displayed uniform intensity throughout their luminal epithelial cells, and 0% representing the absence of BRK nuclear staining. Glands with BRK nuclear staining similar to that seen in the nuclei of normal prostate epithelial cells were assigned two plus signs (++). Glands with approximately 75% intensity of nuclear staining found in normal glands were assigned a (+), those with approximately 50% were assigned a (+/À), and those with 25% or less BRK positive nuclei were assigned a (À). The patterns of BRK expression that were observed in the 58 surgical samples are summarized in Table 1 .
Nuclear expression of BRK was a hallmark of normal glands and in 70% of benign prostatic hyperplasia (BPH). Intense staining of the nuclei was also detected in one gland undergoing atrophy resulting from normal aging and in another normal condition known as transitional cell metaplasia. Nuclear expression of BRK was not observed in any of the glands with highgrade prostatic intraepithelial neoplasia (PIN), considered a precancerous condition. Typical nuclear staining in BPH tissues and the lack of nuclear staining of PIN tissues are shown in Figure 2 .
All grades of differentiation as determined by the Gleason scale were observed in the biopsies except Gleason grade 1. Some degree of BRK nuclear staining was observed in all grades, except grade 5. However, the intensity of the nuclear stain was much less than in normal tissues and this decreased with increasing grade (Figure 3 ). Figure 4 shows a Gleason grade 4 region of a tumor with a few positively stained nuclei (arrows) surrounded by a sheet of epithelial cells with negatively stained nuclei. The BRK positive nuclei are in cells that appear most differentiated within this tumor and resemble a poorly differentiated gland. Prostate tumors are histologically heterogeneous, consisting of many normal and several varying grades of tumor within the same tissue. Every normal gland observed adjacent to tumor glands was positive for BRK staining. Four of the tumors were negative for BRK staining in the nuclei of secretory epithelial cells.
We next sought to determine if the nuclear to cytoplasmic translocation of BRK observed in multiple samples from different patients was occurring in cells of different pathologic states within a single patient. Biopsy samples of a single patient with normal, BPH, PIN, and glands scored as Gleason 2-4 were examined by immunohistochemistry as above (data not shown). As expected, nuclei in epithelial cells of the normal and BPH glands were positive. PIN had no positive nuclei. While nuclear staining was observed in glands of Gleason 2-4, the intensity of the stain decreased as the grade increased, supporting the data collected from samples from different individual patients.
To determine if BRK expression levels change during the progression of prostate cancer, protein lysates were prepared from nine frozen primary prostate tumor biopsies from patients with various stages of metastatic disease. Three of these tumors were from patients with stage B cancer, three with stage C, and three with stage D. Stage B is a palpable tumor that is present in the prostate gland. Stage C is a tumor that has broken through the gland and is considered extracapsular. Stage D is fully metastatic outside the pelvic region. Sections of the frozen tumors were adhered to slides or collected in microfuge tubes and homogenized in protein lysis buffer. Lysates were resolved by SDS-PAGE and immunoblotting was performed with anti-BRK and anti-keratin 18 antibodies ( Figure 5 ). In contrast to lysates from prostate cell lines (see Figure 7) , we detected multiple bands representing BRK in tissue lysates prepared from frozen biopsy samples. Since the frozen tissue had undergone freezing and thawing, the multiple bands may reflect altered modification/stability of the BRK protein that is apparent because of the handling process. We did not detect a significant reproducible difference in BRK protein levels in prostate tumors of different stages after levels of BRK expression were normalized to the number of epithelial cells (Keratin 18 expression) in each sample (Figure 5a ). Parallel stained histological sections from three of the frozen tumor samples is shown in Figure 5b . Samples B3 and C5 have many epithelial glandular structures, while sample D9 has few glands. Thus, it appears that the intracellular localization, not the level of BRK expression, is the main alteration in BRK occurring during the progression of prostate cancer.
Localization of Sam68 is unaltered in high-grade prostate tumors
Since BRK localization changes as tumors dedifferentiate, we examined the possibility that the localization of Sam68, a substrate of BRK, was also affected by the state of differentiation of the tumor. Sam68 was localized in human and mouse prostate using immunohistochemistry. Sam68 was detected in nuclei of luminal epithelial cells in both human and mouse prostate (Figure 6a) . Sections from the same tumor tissue blocks used to study BRK localization above were stained with anti-Sam68 antibodies and examined by light microscopy. While BRK shows loss of nuclear localization in the less-differentiated tumors, Sam68 localization was unchanged in the BPH, PIN, and tumor samples compared with its expression pattern in normal tissues. Figure 6b shows Sam68 and BRK localization in a Gleason grade 4 tumor and in PIN.
Decreased BRK activity is associated with altered localization in the poorly differentiated PC3 human prostate tumor cell line
We compared BRK expression in several human carcinoma cell lines, including the LNCaP and PC3 prostate tumor cell lines, HeLa cells, the MCF7 breast tumor cell line, and the HT29 and SW480 colon carcinoma cell lines (Figure 7) . Cell lysates were separated by SDS-PAGE and immunoblotting was performed with anti-BRK antibodies. BRK protein was detected in all of the human carcinoma cell lines. A comparison of the two prostate cell lines, PC3 and LNCaP, indicates a slightly higher level of expression in the PC3 cells.
LNCaP and PC3 cell lines represent two different spectrums of prostate cancer. PC3 cells are highly aggressive and metastasize in nude mice. The cells also grow in the absence of androgens and are poorly differentiated (Kaighn et al., 1979) . In contrast LNCaP cells do not form metastatic tumors in nude mice, respond to androgens, and maintain differentiated characteristics (Horoszewicz et al., 1980; Lim et al., 1993) . Above, we demonstrated that BRK is a nuclear protein in normal differentiated prostate glands, but nuclear localization decreases in PIN and in prostate tumors of higher Gleason grades. To examine the localization of BRK in LNCaP and PC3 cells, the cells were grown on chamber slides, fixed, and incubated with anti-BRK and/or Sam68 antibodies. Endogenous BRK was detected throughout the cytoplasm as well as in distinct nuclear dots in LNCaP cells, while BRK staining was present in the cytoplasm but absent from the nuclei of PC3 cells (Figure 8a ). Our results with these two cell lines closely parallel what we observed with the human tumor tissues, with nuclear localization being present in the more differentiated cells. Previously we showed that BRK localizes to distinct nuclear bodies known as SNBs in the HT29 colon and MCF7 breast cancer cell lines. To determine if the nuclear dots detected in LNCaP cells were Sam68 containing SNBs, the cells were incubated with antibodies against BRK and Sam68 and appropriate secondary antibodies conjugated to rhodamine or FITC, respectively (Figure 8b ). Sam68 and BRK were present in the same nuclear structures in the LNCaP cell line indicating that these structures are SNBs.
Nuclear association of BRK and Sam68 in LNCaP was further confirmed by coimmunoprecipitation experiments. Immunoprecipitations were performed with LNCaP and PC3 nuclear lysates and anti-BRK antibodies followed by immunoblotting with anti-Sam68 antibodies. Lysates were immunoprecipitated with rabbit IgG as a control. A band corresponding to Sam68 was detected in the LNCaP nuclear fraction but not in the PC3 nuclear fraction (Figure 9a ). Immunoblotting was also performed with total cell lysates and anti-Sam68 antibodies to show endogenous expression of Sam68 in these prostate tumor cell lines and with anti-keratin 18 antibodies as a loading control.
To determine if altered localization of BRK might affect its activity, in vitro kinase assays were performed. Immunoprecipitations were performed with BRK antibodies and lysates from LNCaP and PC3 cells followed by incubation with [g 32 P]ATP and kinase buffer. No exogenous substrate was used since BRK can undergo autophosphorylation. Proteins were resolved on SDS-PAGE and transferred to a nitrocellulose membrane that was exposed to film to detect phosphorylated proteins (Figure 9b ). Bands were detected in both samples migrating at the size of BRK. Immunoblotting was subsequently performed with the membrane and anti-BRK antibodies to confirm the identity of these bands and to control for the amount of protein present in the assay (Figure 9b, bottom panel) . Although a lower amount of BRK was immunoprecipitated from LNCaP cells, its activity was significantly higher suggesting that nuclear localization of the kinase may influence its activity.
Discussion
Aberrant tyrosine kinase signaling via stimulation of growth factor receptors or intracellular tyrosine kinases such as Src, has been shown to contribute to the development of a variety of human cancers (BlumeJensen and Hunter, 2001) . BRK/Sik has a structure similar to that of the Src-family kinases, but cloned cDNAs encoding both human and mouse proteins indicate the lack of an amino-terminal myristoylation signal indicating that the kinase is not specifically targeted to the membrane. Intracellular localization of BRK/Sik appears to have flexibility, and although it lacks an identified nuclear localization signal, it has been found in the nucleus associated with its substrate, Sam68 (Derry et al., 2000) . Here we have shown that the orthologous intracellular kinases BRK and Sik are localized to the nuclei of human and mouse prostate epithelial cells, respectively. The normal prostate is the first tissue in which distinct nuclear localization of the BRK/Sik kinase has been observed.
We examined BRK expression in a panel of human prostate biopsy samples including BPH, high-grade PIN, and various grades of prostate tumors to determine if BRK might play a role in prostate cancer.
As in normal prostate tissues, nuclear localization of BRK was observed in most benign secretory cells of BPH biopsies. However, in areas of extensive epithelial infolding in BPH, BRK was absent or only faintly detected in the nuclei of glandular epithelial cells (Figure 2 ). All nuclei observed in PIN were negative for BRK staining.
We found that nuclear localization of BRK in secretory epithelial cells in prostate adenocarcinoma correlates with the grade of prostate tumor, with nuclear expression being higher in low-grade and lower in highgrade regions of the tumors. Although the nuclear Figure 6 The BRK substrate Sam68 retains its nuclear localization in prostate tumors of different grades. (a) Nuclear staining of Sam68 is clearly evident in the luminal epithelial cells of normal mouse and human prostate. (b) Tissue samples from a patient with Gleason 4 tumor and a patient with PIN were incubated with antibodies against Sam68 or BRK. While BRK is absent from the nuclei of the epithelial cells in both Gleason 4 and PIN, nuclear staining of Sam68 is maintained. Size bars represent 100 mm localization of BRK was altered, the overall levels of BRK expression corresponded well with the amount of epithelial cells as determined by examining keratin expression, and did not appear to change significantly during prostate tumor progression.
A correlation between decreased BRK nuclear localization and increased tumorigenicity was also observed in prostate tumor cell lines. BRK expression was detected in the nucleus in the LNCaP cell line, but not in the more tumorigenic, androgen-independent PC3 cell line. While overall levels of BRK expression were higher in PC3 cells, its activity in PC3 cells was decreased compared with its activity in LNCaP cells. Thus, nuclear localization of BRK correlated with higher BRK activity in a more differentiated prostate tumor cell line, whereas cytoplasmic localization of BRK correlated with decreased BRK activity in a poorly differentiated prostate tumor cell line.
The present study provides evidence that the relation between BRK/Sik and its nuclear substrate, Sam68, may be important for maintaining proper cell growth and LNCaP cells were fixed and stained with anti-BRK antibodies followed by staining with anti-Sam68 antibodies. BRK was visualized with rhodamine and Sam68 with FITC. Nuclei were stained with DAPI. The composite shows colocalization as yellow spots in the nuclei. As a control, LNCaP cells were incubated with rabbit IgG followed by mouse IgG and no distinct signal was observed (bottom row). The size bar represents 10 mm differentiation in the prostate gland. We previously demonstrated that BRK/Sik negatively regulates the RNA-binding activity of Sam68 (Derry et al., 2000) . Although BRK is absent from the nuclei of PIN and poorly differentiated tumors, Sam68 nuclear localization remains unaltered. Since phosphorylation of Sam68 by BRK inhibits Sam68 RNA-binding activities, loss of nuclear BRK may lead to activation of Sam68 functions and unregulated RNA transport or processing, leading to uncontrolled cell cycle progression and loss of welldifferentiated glands. In addition, the translocation of BRK from the nucleus to the cytoplasm in PIN and prostate tumors may give it access to additional substrates, leading to the activation of presently unidentified signaling pathways.
Our data suggest a role for the nuclear tyrosine kinase BRK in the normal prostate and during the development of prostate cancer. Decreased nuclear localization and activity of BRK in prostate glands are associated with poor differentiation. Since poorly differentiated prostate epithelial cells are associated with more aggressive prostate tumors, localization of BRK may prove to be an important marker for distinguishing tumors that are likely to remain dormant and those with increased potential to become aggressive. In addition, identification of additional nuclear BRK/Sik substrates may provide new potential targets for therapies aimed at slowing or stopping tumor growth.
Materials and methods

Cell lines and human tissue samples
Cell lines were obtained from the American Type Culture Collection. All cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% bovine calf serum except PC3 and LNCaP cells, which were maintained in RPMI with 10% bovine calf serum. Tissue samples were prospectively collected at the time of surgery for radical prostatectomy at Michael Reese Hospital, Chicago, IL, in accordance with IRB guidelines.
Immunohistochemistry
Tissue immunohistochemistry was performed as previously described using the TSA-Indirect Kit from Dupont/NEN (Boston, MA) (Llor et al., 1999) . Antigen retrieval was performed on hydrated paraffin sections of mouse or human tissue by microwaving in 1 mm EDTA pH 8.0 on high power 3 times for 5 min each or treatment with proteolytic enzymes (Auto/Zyme, Vector, Burlingame, CA, USA). Sections were incubated in block buffer with anti-Sik or anti-BRK polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) (dilutions from 1 : 200 to 1 : 1000) overnight at 41C. Controls included incubation with equal dilutions of rabbit IgG or buffer alone. Signals were visualized with DAB (Vector Laboratories, Burlingame, CA, USA) and analysed by light microscopy.
Cultured cells were grown on chamber slides and fixed in methanol at À201C for 5 min or Carnoy's fixative for 5 min at 32 P-labeled phosphorylated proteins were resolved by SDS-PAGE and transferred to a membrane and exposed to film. The level of autophosphorylated BRK is higher in LNCaP cells. The lower panel shows anti-BRK antibody binding to the same membrane and indicates the amount of BRK protein immunoprecipitated in the reaction. The amount of BRK protein in the PC3 sample is much higher than in the LNCaP sample, indicating BRK activity is significantly higher in LNCaP cells than in PC3 cells room temperature. BRK antibody staining of cultured cells was visualized with rhodamine-avidin DAB (Vector Laboratories, Burlingame CA, USA) (1 : 500). For double antibody labeling, cells were stained with rabbit anti-BRK and visualized with rhodamine, followed by incubation with antiSam68 (BD Biosciences, San Jose, CA, USA) (1 : 50) for 1 h at room temperature and anti-mouse IgG FITC conjugate (Sigma, St Louis, MO, USA) (1 : 64).and nuclei were stained with DAPI (Roche Applied Science, Indianapolis, IN, USA). Controls were performed by incubation with buffer alone, rabbit serum, or rabbit IgG before incubation with secondary antibody. Results were analysed by confocal microscopy.
Immunoblotting
Cultured cells were lysed as described (Vasioukhin and Tyner, 1997) . Frozen prostate tumor samples were cut by a cryostat and 10 sections were collected in an eppendorf tube. Tissues were homogenized in 150-250 ml of cold lysis buffer as above and lysed on ice with constant agitation for 1 h. Samples were spun in a centrifuge for 10 min at 41C at 14000 r.p.m. Immunoblotting was performed as previously described (Vasioukhin and Tyner, 1997) .
Cell fractionation and immunoprecipitations and kinase assays
Cells were washed two times with 1 Â PBS followed by one wash with hypotonic lysis buffer (HLB: 20 mm Tris-HCl pH 7.5, 1 mm MnCl 2 , 2 mm EGTA) for 5 min on ice. Cells were then covered with 1.5 ml HLB containing 20 mg/ml leupeptin and 1 mm PMSF per plate, scraped, and transferred to a 15 ml tube and agitated on ice for 20-30 min. Cells were then homogenized in a Dounce homogenizer (50-60 strokes) and spun for 10 min at 2300 r.p.m. at 41C to separate the nuclei. The pellet was washed in 1 ml of HLB and resuspended in 1 ml Dignum buffer (20 mm HEPES pH 7.9, 420 mm NaCl, 1.5 mm MnCl 2 , 0.1 mm EDTA, 25% glycerol, 0.5 mm DTT, 0.5 mm PMSF, 2 mg/ml leupeptin, 2 mg/ml aprotinin, and 1 mm NaVO 4 ). Nuclei were then agitated on a rotary shaker for 15 min at 41C, spun for 10 min at 14000 r.p.m. at 41C. The supernatant was kept as the nuclear fraction. Immunoprecipitations (Derry et al., 2000) and in vitro kinase assays (Vasioukhin and Tyner, 1997 ) were performed as previously described.
